Cargando…
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Guidelines have increasingly stressed the concept that adequate glycemic control is required to prevent or decrease the macro- and microvascular complications of type 2 diabetes mellitus (T2DM). PPAR-gamma agonists (“glitazones”) are no longer prioritized due to their effects on heart failure. Howev...
Autores principales: | Giglio, Rosaria Vincenza, Papanas, Nikolaos, Rizvi, Ali Abbas, Ciaccio, Marcello, Patti, Angelo Maria, Ilias, Ioannis, Pantea Stoian, Anca, Sahebkar, Amirhossein, Janez, Andrej, Rizzo, Manfredi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609741/ https://www.ncbi.nlm.nih.gov/pubmed/36295635 http://dx.doi.org/10.3390/medicina58101475 |
Ejemplares similares
-
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2023) -
Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2022) -
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2021) -
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
por: Popovic, Djordje S., et al.
Publicado: (2021) -
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
por: Nikolic, Dragana, et al.
Publicado: (2022)